Compare TBBK & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TBBK | NVAX |
|---|---|---|
| Founded | 1999 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 1.6B |
| IPO Year | 2005 | 1996 |
| Metric | TBBK | NVAX |
|---|---|---|
| Price | $58.10 | $8.52 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 9 |
| Target Price | ★ $69.00 | $11.33 |
| AVG Volume (30 Days) | 411.8K | ★ 3.5M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 14.69 | ★ 309.76 |
| EPS | ★ 4.92 | 2.58 |
| Revenue | $141,147,000.00 | ★ $1,123,479,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.16 | N/A |
| P/E Ratio | $11.69 | ★ $3.26 |
| Revenue Growth | 20.85 | ★ 64.69 |
| 52 Week Low | $41.46 | $5.35 |
| 52 Week High | $81.65 | $11.85 |
| Indicator | TBBK | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 63.34 | 45.32 |
| Support Level | $50.85 | $8.01 |
| Resistance Level | $71.63 | $9.05 |
| Average True Range (ATR) | 1.63 | 0.45 |
| MACD | 0.87 | -0.09 |
| Stochastic Oscillator | 77.88 | 41.48 |
The Bancorp Inc is a financial holding company. The Company's operations are classified under three segments: fintech, Credit Solutions (three sub-segments), and corporate. The fintech segment includes the deposit balances and non-interest income generated by prepaid, debit, and other card-accessed accounts, ACH processing, and other payments-related processing. It also includes loan balances and interest and non-interest income from credit products generated through payment relationships; Credit Solutions includes REBL (real estate bridge lending), comprised of apartment building rehabilitation loans, and Others; Corporate includes the Company's investment securities, corporate overhead, and expenses which have not been allocated to segments.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.